Wiley Bros. Aintree Capital, LLC Zai Lab LTD Transaction History
Wiley Bros. Aintree Capital, LLC
- $14.9 Billion
- Q3 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Zai Lab LTD stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 7,100 shares of ZLAB stock, worth $154,425. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,100
Previous 6,469
9.75%
Holding current value
$154,425
Previous $226,000
6.19%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ZLAB
# of Institutions
154Shares Held
32.7MCall Options Held
168KPut Options Held
222K-
Capital World Investors Los Angeles, CA6.08MShares$132 Million0.03% of portfolio
-
Clearbridge Investments, LLC New York, NY3.52MShares$76.5 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY2.29MShares$49.8 Million1.04% of portfolio
-
Janus Henderson Group PLC London, X02.05MShares$44.6 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA1.72MShares$37.4 Million0.01% of portfolio
About Zai Lab Ltd
- Ticker ZLAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,908,704
- Market Cap $2.13B
- Description
- Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...